REMAIN: Feasibility and Acceptability of Problem Management Plus (PM+) for Refugee Youth Living in the Netherlands

Implementation of PM+ in refugee adolescents and youth: Pilot RCT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON24354

Enrollment

Registered

2020-07-03

Start date

2020-07-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common mental disorders Depression Anxiety Post-traumatic stress disorder Scalable interventions Refugee youth

Interventions

There are three arms in this study. Treatment Group 1: Problem Management Plus (PM+) Program The first treatment group will receive WHO´s Problem Management Plus (PM+) program in addition to care-as-

De Graaf et al., 2020

Rahman, Riaz, et al., 2016) and group format (Rahman et al., 2019). Even though the intervention mainly designed for LMIC, its feasibility has been evaluated for high resource countries as well (eg. D

Eligibility

Inclusion criteria

Inclusion criteria: - 16 to 25 years old - Syrian, Eritrean or Iraqi background - Elevated levels of psychological distress (K10>15) and reduced psychosocial functioning (WHODAS 2.0>16)

Exclusion criteria

Exclusion criteria: - Acute medical conditions - Imminent suicide risk or expressed acute needs and protection risks. - Severe mental disorder (psychotic disorders, substance-dependence) - Severe cognitive impairment (e.g. severe intellectual disability) - Currently receiving a psychological treatment within specialized mental health care - In case of current psychotropic medication use: change in dosage during the past 2 months.

Design outcomes

Primary

Measure	Time frame
The primary outcome of this study will be the feasibility and acceptability of PM+ interventions.	—

Secondary

Measure	Time frame
Psychological distress: HSCL-25	—

Contacts

Public ContactCansu Alozkan Sever

Vrije Universiteit Amsterdam

c.alozkan@vu.nl+31205985096

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)